title: [Comparison of different drug-eluting stents in the treatment of coronary artery disease: a single center four-year clinical follow-up].
abstract: OBJECTIVE
  To investigate the outcomes of sirolimus-eluting stent (Cypher, Cordis/Johnson & Johnson, Warren, NJ, USA) and paclitaxel-eluting stent (Taxus, Boston Scientific, Natick, MA, USA) in the treatment of coronary heart disease after a four-year clinical follow-up.
  
  
  METHODS
  237 consecutive patients were enrolled in this study and treated with Cypher (136 patients) or Taxus (101 patients) from January to October 2003. The rates of stenosis, stent thrombosis according to ARC definition and major adverse cardiac events (MACE a composite of cardiac death, myocardial infarction and target vessel revascularization) were analysed.
  
  
  RESULTS
  There was no significant difference on secondary restenosis, target lesion revascularization (TLR) and MACE between Cypher and Taxus groups at six-month angiographic follow-up, but late luminal loss was higher in Taxus group [(0.15 +/- 0.43) mm vs (0.42 +/- 0.34) mm, P = 0.022]. At four-year follow-up, TVR-free survival rate was 88.97% in Cypher group versus 82.28% in Taxus group (P = 0.158). MACE-free survival rate was 83.8% in Cypher group and 79.2% in Taxus group (P = 0.056). The incidence of stent thrombosis was no difference between the two groups (1.47% vs 1.98%). There was also no difference among early (0 vs 0.99%), late (0.73% vs 0.99%) and very late stent thrombosis (0.73% vs 0) between the 2 groups.
  
  
  CONCLUSIONS
  There were no difference between Cypher and Taxus in the treatment of coronary artery disease; Both Cypher and Taxus have good clinical outcomes except that Taxus had higher late loss.
authors.affiliation: Department of Coronary Heart Disease, Cardiovascular Institute Fuwai Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China.
authors.forename: Li-Jian
authors.initials: LJ
authors.lastname: Gao
authors.forename: Ji-Lin
authors.initials: JL
authors.lastname: Chen
authors.forename: Jun
authors.initials: J
authors.lastname: Chen
authors.forename: Run-Lin
authors.initials: RL
authors.lastname: Gao
authors.forename: Yue-Jin
authors.initials: YJ
authors.lastname: Yang
authors.forename: Bo
authors.initials: B
authors.lastname: Xu
authors.forename: Xue-Wen
authors.initials: XW
authors.lastname: Qin
authors.forename: Shu-Bin
authors.initials: SB
authors.lastname: Qiao
authors.forename: Min
authors.initials: M
authors.lastname: Yao
authors.forename: Hai-Bo
authors.initials: HB
authors.lastname: Liu
authors.forename: Yong-Jian
authors.initials: YJ
authors.lastname: Wu
authors.forename: Jin-Qing
authors.initials: JQ
authors.lastname: Yuan
authors.forename: Jue
authors.initials: J
authors.lastname: Chen
mesh_terms: D000368:Aged; D003324:Coronary Artery Disease / Q000188:drug therapy*; D054855:Drug-Eluting Stents; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D012189:Retrospective Studies; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D020123:Sirolimus